Target
Vβ10 TCR
1 abstract
Abstract
Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment.Org: Marengo Therapeutics, Center for Immuno-Oncology, CCR, NCI, NIH, Center for Immuno-Oncology, CCR, NCI, NIH, Gustave Roussy Cancer Campus, Department of Surgery, Massachusetts General Hospital, Harvard Medical School,